RxDoctor Payments DataLook up a doctor →

Thomas Coleman, MD

Urology · Mobile, ALNPI 1245348218

Payments from drug & device makers

$14,042in general payments, 2019–2025

Across 296 payments — averaging $47.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cornerstone Urology Network, LLC$7K
  • Johnson & Johnson$979
  • Coloplast$523
  • Neotract Inc.$515
  • Teleflex LLC$431
  • Sumitomo Pharma America, Inc.$393
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,042 in reported general payments places this provider in the 80th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$342,901
Medicare patients
439
Services billed
8,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide38$516,276
XtandiEnzalutamide26$344,204
OrgovyxRelugolix104$269,652
MyrbetriqMirabegron79$50,719
GemtesaVibegron62$36,192
Tamsulosin Hcl591$7,442
Testosterone Cypionate116$5,017
Finasteride290$3,210
Testosterone37$3,072
Bethanechol Chloride57$2,485
Alfuzosin Hcl ErAlfuzosin Hcl80$1,882
Methenamine Hippurate23$1,876
Bicalutamide32$1,424
Oxybutynin Chloride ErOxybutynin Chloride41$1,053
Oxybutynin Chloride45$919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$979$516,27638 claims
Astellas Pharma US IncXtandi, Myrbetriq$358$394,923105 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$393$305,845166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 179 urology providers in Alabama.

Other urology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →